Growth Metrics

Eli Lilly (LLY) Net Cash Flow (2016 - 2026)

Eli Lilly filings provide 18 years of Net Cash Flow readings, the most recent being -$2.1 billion for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 568.73% to -$2.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.9 billion, a 147.01% increase, with the full-year FY2025 number at $3.6 billion, up 386.33% from a year prior.
  • Net Cash Flow hit -$2.1 billion in Q1 2026 for Eli Lilly, up from -$2.5 billion in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $6.4 billion in Q3 2025 to a low of -$2.5 billion in Q4 2025.
  • Median Net Cash Flow over the past 5 years was -$81.5 million (2024), compared with a mean of $77.7 million.
  • Biggest five-year swings in Net Cash Flow: crashed 16689.47% in 2023 and later skyrocketed 7933.5% in 2025.
  • Eli Lilly's Net Cash Flow stood at -$422.2 million in 2022, then surged by 173.07% to $308.5 million in 2023, then increased by 6.13% to $327.4 million in 2024, then tumbled by 850.27% to -$2.5 billion in 2025, then grew by 16.42% to -$2.1 billion in 2026.
  • The last three reported values for Net Cash Flow were -$2.1 billion (Q1 2026), -$2.5 billion (Q4 2025), and $6.4 billion (Q3 2025) per Business Quant data.